
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
about 28 years ago
Optimizing Antimicrobial Therapy and Emerging Pathogensabout 28 years ago
Participating Facultyabout 28 years ago
Introductionabout 28 years ago
Mechanisms and Current Rates of Resistanceabout 28 years ago
Therapeutic Pathways for Antimicrobial Use: General Overviewabout 28 years ago
Therapeutic Pathways for Antimicrobial Use: Pediatric Issuesabout 28 years ago
Pharmacoeconomic Impact of Appropriate Clinical Pathwaysabout 28 years ago
CME Quiz





